Pulmonary Arterial Hypertension: Combination Therapy in Practice

被引:48
|
作者
Burks, Marsha [1 ]
Stickel, Simone [2 ]
Galie, Nazzareno [3 ]
机构
[1] Univ Michigan, UM Frankel Cardiovasc Ctr, Ann Arbor, MI 48109 USA
[2] Univ Hosp, Dept Pulmonol, Zurich, Switzerland
[3] Univ Bologna, Dept Invest Diagnost & Specialty Med, Bologna, Italy
关键词
INHALED ILOPROST; BOSENTAN; EPIDEMIOLOGY; NONADHERENCE; ANTAGONIST; REGISTRY;
D O I
10.1007/s40256-018-0272-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Combination therapy is now regarded as the standard of care in pulmonary arterial hypertension (PAH) and is becoming widely used in clinical practice. Given the inherent complexities of combining medications, there is a need for practical advice on implementing this treatment strategy in the clinic. Drawing on our experience and expertise, within this review, we discuss some of the challenges associated with administration of combination therapy in PAH and how these can be addressed in the clinic. Despite their differing modes of action, all of the currently available classes of PAH therapy induce systemic vasodilation. In initial combination therapy regimens in particular, this may lead to additive side effects and reduced tolerability compared with monotherapy. However, approaches such as staggered treatment initiation and careful up-titration may reduce the risk of additive side effects and have been used successfully in clinical practice, as well as in clinical trials and registry studies. When combination therapy regimens are initiated, it is important that patients are monitored regularly for the presence of any side effects and that these are then managed promptly and appropriately. For patients to attain the best outcomes, the treatment regimen must be tailored to the individual's specific needs, including consideration of PAH etiology, the presence of comorbidities and concomitant medications beyond PAH therapy, and patient lifestyle and preference. It is also vital that individuals are managed at expert care centers, where multidisciplinary teams have a wealth of specialist experience in treating PAH patients. Adherence to therapy can be a concern in a chronic disease such as PAH, and as treatment regimens become increasingly complex, maintaining good treatment adherence may become more challenging. It is essential that patients are educated on the importance of treatment adherence, and this is a key role for the PAH nurse specialist. For patients who are managed carefully in expert centers with combination therapy regimens that are tailored to their specific needs, a favorable benefit-risk ratio can be achieved. With individual and carefully managed approaches, the excellent results observed with combination therapy in clinical trials can be obtained by patients in a real-world setting.
引用
收藏
页码:249 / 257
页数:9
相关论文
共 50 条
  • [41] Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
    Hoeper, MM
    Markevych, I
    Spiekerkoetter, E
    Welte, T
    Niedermeyer, J
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (05) : 858 - 863
  • [42] Initiate and Aggressive Combination Therapy for Severe Idiopathic Pulmonary Arterial Hypertension
    Maki, Hisataka
    Inaba, Toshiro
    Shiga, Taro
    Hatano, Masaru
    Yao, Atsushi
    Kinugawa, Kouichiro
    Hirata, Yasunobu
    Nagai, Ryozo
    Yamashita, Takeshi
    Aizawa, Tadanori
    [J]. JOURNAL OF CARDIAC FAILURE, 2010, 16 (09) : S171 - S171
  • [43] Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension
    Haarman, Meindina G.
    Levy, Marilyne
    Roofthooft, Marcus T. R.
    Douwes, Johannes M.
    Vissia-Kazemier, Theresia R.
    Szezepanski, Isabelle
    Berger, Rolf M. F.
    Bonnet, Damien
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 57 (01)
  • [44] Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
    Jansa, Pavel
    Pulido, Tomas
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2018, 18 (01) : 1 - 11
  • [45] Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension
    Papa, Silvia
    Badagliacca, Roberto
    D'alto, Michele
    Ghio, Stefano
    Argiento, Paola
    Bellomo, Vincenzo
    Brunetti, Natale Daniele
    Casu, Gavino
    Confalonieri, Marco
    Corda, Marco
    Correale, Michele
    D'agostino, Carlo
    De Michele, Lucrezia
    Galgano, Giuseppe
    Graco, Alessandra
    Lombardi, Carlo
    Luongo, Federico
    Manzi, Giovanna
    Mercurio, Valentina
    Miotti, Cristiano
    Mule, Massimiliano
    Paciocco, Giuseppe
    Romeo, Emanuele
    Scelsi, Laura
    Scoccia, Gianmarco
    Toto, Federica
    Stolfo, Davide
    Vitulo, Patrizio
    Naeije, Robert
    Vizza, Carmine Dario
    Fedele, Francesco
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N49 - N49
  • [46] Prediction of the Prognosis of Idiopathic Pulmonary Arterial Hypertension in the Young with Combination Therapy
    Matsuura, H.
    Nakayama, T.
    Ikehara, S.
    Takatsuki, S.
    Saji, B. T.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [47] Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
    Sitbon, Olivier
    Jais, Xavier
    Savale, Laurent
    Cottin, Vincent
    Bergot, Emmanuel
    Macari, Elise Artaud
    Bouvaist, Helene
    Dauphin, Claire
    Picard, Francois
    Bulifon, Sophie
    Montani, David
    Humbert, Marc
    Simonneau, Gerald
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (06) : 1691 - 1697
  • [48] LESSONS LEARNED FROM TRIPLE COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION
    Schuster, Sheeja
    Sulica, Roxana
    [J]. CHEST, 2019, 156 (04) : 493A - 494A
  • [49] Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges
    Lajoie, Annie-Christine
    Bonnet, Sebastien
    Provencher, Steeve
    [J]. PULMONARY CIRCULATION, 2017, 7 (02) : 312 - 325
  • [50] Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension
    Hatano, Masaru
    Abe, Kohtaro
    Koike, George
    Takahashi, Tomohiko
    Tunmer, Grant
    Kiely, David G.
    [J]. INTERNATIONAL HEART JOURNAL, 2022, 63 (01) : 99 - 105